he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源重定向
上一页:哪些杀菌药物可诱发癫痫?
- 2022-05-04儿童癫痫病的征状表现有哪些
- 2022-05-02秋冬季感冒高发,病症患者感冒期间,如何用药?
- 2022-04-252013年国际抗癫痫该协会抗癫痫药使用指南
- 2022-02-28千万别忽视女婴癫痫病症状
- 2022-02-28小儿癫痫病症状展现
- 2022-02-21成年人为什么会患癫痫病 癫痫病症状
- 2016AAN:神经专家发表了有前途的专业见解
- 癫痫患者手术评估新型工具
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- 抗癫痫药物预防新发癫痫:任重而道远
- 癫痫猝死:凶手是谁?
- 如何治疗女性癫痫?
- 癫痫患者春节期间的饮食问题
- 黑芝麻的营养价值 吃黑芝麻的好处
- 北京哪家癫痫医院排名好,成本低
- 癫痫治疗障碍仍难以克服
- 羊角病能生孩子吗?
- FDA批准Aptiom用于治疗患者癫痫发作
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 2015第31届国际癫痫大会(IEC)
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 特发性癫痫大发作药物治疗的首选
- 不注意这些问题,吃多少药都没用!
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 预测癫痫患者再入院风险
- 2013国际抗癫痫联合会抗癫痫药用指南
- 三庚酸酯可治疗1型转运体缺陷综合征
- Medpage Today:不同类型的抗癫痫药物更有利
- GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 继续做癫痫病需要多少钱
- 癫痫病治疗哪家美味什么好呢
- 专家告诉你癫痫病的治疗好作法
- 治疗癫痫病要花费多少钱 全力以赴护理也会减少费用
- 【用药问答】特发性发作大发作药物治疗首选?
- 癫痫病的发作有哪些病变
- 使用唑 3 天后,患者发生躁狂砸了监护仪?!这类抗生素脑病值得警惕!
- 治疗小儿癫痫病要多一大笔钱
- 以前癫痫病的症状都有什么
- 小儿抽搐证怎么病患是癫痫病吗
- 治疗中风疾病要花多少钱 尽早治疗会减少费用
- Medpage Today:不同类别抗癫痫药物的联用更利于
- 千万别忽视女婴癫痫病症状